AHA
MCID: ANM038
MIFTS: 62

Anemia, Autoimmune Hemolytic (AHA)

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Anemia, Autoimmune Hemolytic

MalaCards integrated aliases for Anemia, Autoimmune Hemolytic:

Name: Anemia, Autoimmune Hemolytic 56
Autoimmune Hemolytic Anemia 12 74 52 58 36 29 54 15 71
Idiopathic Autoimmune Hemolytic Anemia 52 71
Anemia, Hemolytic, Autoimmune 43 17
Immuno-Hemolytic Anemia 52 71
Familial Auto-Immune Hemolytic Anemia 52
Acquired Autoimmune Hemolytic Anemia 52
Autoimmune Haemolytic Anaemia 12
Autoimmune Hemolytic Anaemia 12
Anemia Hemolytic Autoimmune 52
Aiha 58
Aha 58

Characteristics:

Orphanet epidemiological data:

58
autoimmune hemolytic anemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: elderly;

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
anemia, autoimmune hemolytic:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:718
OMIM 56 205700
KEGG 36 H01585
ICD9CM 34 283.0
MeSH 43 D000744
NCIt 49 C34378
SNOMED-CT 67 413603009
MESH via Orphanet 44 D000744
ICD10 via Orphanet 33 D59.0 D59.1
UMLS via Orphanet 72 C0002880
Orphanet 58 ORPHA98375
MedGen 41 C0002880
UMLS 71 C0002880 C0543663 C2931849

Summaries for Anemia, Autoimmune Hemolytic

KEGG : 36 Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by the increased destruction of red blood cells (RBCs) by anti-RBC autoantibodies with or without complement activation. AIHAs can be distinguished on the basis of the autoantibody Ig class and thermal characteristics, i.e. the optimal temperature of reaction with autologous erythrocytes, in warm (wAIHA), cold (cold agglutinin disease; CAD), and mixed forms, although atypical cases of difficult diagnostic classification are reported with increasing frequency. Moreover, AIHAs are classified in primary (idiopathic), in which hemolysis dominates the clinical picture in the absence of any other coexisting disorder, and in secondary forms, accompanying and complicating an underlying disease. AIHA may develop gradually, or have a fulminant onset with life-threatening anemia. The diagnosis is usually simple, based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test (DAT).

MalaCards based summary : Anemia, Autoimmune Hemolytic, also known as autoimmune hemolytic anemia, is related to autoimmune lymphoproliferative syndrome, type iia and autoimmune lymphoproliferative syndrome, type v. An important gene associated with Anemia, Autoimmune Hemolytic is HP (Haptoglobin), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Mycophenolic acid and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include testes, b cells and t cells, and related phenotypes are muscle weakness and fatigue

Disease Ontology : 12 An autoimmune disease of blood that is characterized by deficient red blood cells caused by auto-antibodies.

NIH Rare Diseases : 52 Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells . This causes a drop in the number of red blood cells , leading to hemolytic anemia . Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties , jaundice , dark urine and/or splenomegaly . AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly. There are two main types of autoimmune hemolytic anemia : warm antibody hemolytic anemia and cold antibody hemolytic anemia . Treatment may include corticosteroids such as prednisone , splenectomy, immunosuppressive drugs and/or blood transfusions.

Wikipedia : 74 Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood... more...

More information from OMIM: 205700

Related Diseases for Anemia, Autoimmune Hemolytic

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies Rare Hemolytic Anemia

Diseases related to Anemia, Autoimmune Hemolytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 938)
# Related Disease Score Top Affiliating Genes
1 autoimmune lymphoproliferative syndrome, type iia 32.8 CD8A CD4
2 autoimmune lymphoproliferative syndrome, type v 32.4 CTLA4 CD52 CD5
3 common variable immunodeficiency 32.2 LRBA ICOSLG FOXP3 CTLA4 CD40LG CD19
4 autoimmune lymphoproliferative syndrome 32.1 LRBA ICOSLG FOXP3 CTLA4 CD8A CD40LG
5 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 32.0 HP G6PD FOXP3
6 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.5 LRBA ICOSLG FOXP3 CTLA4 CD8A CD4
7 bilirubin metabolic disorder 31.3 HP G6PD CD40LG
8 lupus erythematosus 31.3 CTLA4 CD40LG C3 C1S
9 hemolytic anemia 31.2 RHCE LRBA HP G6PD CD59 CD55
10 glomerulonephritis 31.1 CD55 CD40LG C3 C1S
11 cryptococcal meningitis 31.0 CD8A CD4 CCR6
12 interstitial nephritis 31.0 ICOSLG CD40LG CCR6
13 cryoglobulinemia, familial mixed 30.9 CD5 CD40LG
14 acute cystitis 30.9 CD40LG CD4 CCR6
15 thrombotic thrombocytopenic purpura 30.9 HP CD40LG C3
16 b cell prolymphocytic leukemia 30.8 CD5 CD19
17 pfeiffer syndrome 30.8 CD8A CD40LG CD4 CD19 CCR6
18 autoimmune disease 30.8 ICOSLG FOXP3 CTLA4 CD55 CD40LG CCR6
19 thrombocytopenic purpura, autoimmune 30.8 LRBA ICOSLG CD52 CD40LG CD4 CCR6
20 cholangitis, primary sclerosing 30.8 ICOSLG CD8A CD40LG CD4 CCR6
21 igg4-related disease 30.8 ICOSLG CD4 CCR6
22 sarcoidosis 1 30.8 ICOSLG CD8A CD40LG CD4 CCR6
23 connective tissue disease 30.8 ICOSLG CD8A CD40LG CD4 CCR6
24 syphilis 30.7 CD8A CD40LG CD4 CCR6
25 plasmodium falciparum malaria 30.7 HP G6PD CD55 CD40LG
26 cll/sll 30.7 CD5 CD19 CCR6
27 viral pneumonia 30.7 CD8A CD40LG CD4 CCR6
28 vasculitis 30.7 CTLA4 CD40LG C3 C1S
29 respiratory failure 30.7 G6PD CD40LG CD4 CCR6
30 miliary tuberculosis 30.7 CD8A CD40LG CD4
31 babesiosis 30.7 HP CD40LG CD4
32 neuroretinitis 30.7 CD40LG CD4
33 parotitis 30.6 G6PD CD40LG CD4
34 prolymphocytic leukemia 30.6 CD52 CD5 CD19
35 hemolytic-uremic syndrome 30.6 HP CD55 CD40LG C3
36 mycobacterium tuberculosis 1 30.6 ICOSLG CD8A CD4 CCR6
37 guillain-barre syndrome 30.6 HP CD40LG CCR6
38 dysgammaglobulinemia 30.6 ICOSLG CD8A CD40LG
39 cryptogenic organizing pneumonia 30.6 CD8A CD40LG CD4
40 paroxysmal nocturnal hemoglobinuria 30.6 HP CD59 CD55 CD52 C3
41 myelitis 30.6 ICOSLG CD40LG CCR6
42 facial paralysis 30.6 CD8A CD40LG CD4
43 autoimmune pancreatitis 30.6 FOXP3 CTLA4 CD40LG CD4
44 pharyngitis 30.5 CD8A CD40LG CD4
45 immune deficiency disease 30.5 ICOSLG FOXP3 CD5 CD40LG CD4 CCR6
46 systemic scleroderma 30.5 ICOSLG CD8A CD40LG CD4 CCR6
47 common cold 30.5 ICOSLG CD4 CCR6
48 neuromyelitis optica 30.5 CD59 CD40LG C3
49 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 ICOSLG CTLA4 CD8A CD4 CCR6
50 acquired angioedema 30.5 HP C3 C1S

Comorbidity relations with Anemia, Autoimmune Hemolytic via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Leukemia, Chronic Lymphocytic
Neutropenia

Graphical network of the top 20 diseases related to Anemia, Autoimmune Hemolytic:



Diseases related to Anemia, Autoimmune Hemolytic

Symptoms & Phenotypes for Anemia, Autoimmune Hemolytic

Human phenotypes related to Anemia, Autoimmune Hemolytic:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dyspnea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002094
4 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
5 hemolytic anemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001878
6 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
7 abnormal leukocyte morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0001881
8 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
9 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
10 lymphoma 58 31 frequent (33%) Frequent (79-30%) HP:0002665
11 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
12 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
13 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
14 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
15 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
16 abnormal urinary color 58 31 occasional (7.5%) Occasional (29-5%) HP:0012086
17 abnormality of metabolism/homeostasis 31 HP:0001939
18 autoimmune hemolytic anemia 31 HP:0001890

Symptoms via clinical synopsis from OMIM:

56
Heme:
autoimmune hemolytic anemia

Lab:
coombs positive
abnormal immunoglobulin in heterozygotes

Clinical features from OMIM:

205700

MGI Mouse Phenotypes related to Anemia, Autoimmune Hemolytic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 C3 CCR6 CD19 CD4 CD40LG CD5
2 homeostasis/metabolism MP:0005376 9.97 C3 CCR6 CD19 CD4 CD40LG CD55
3 immune system MP:0005387 9.77 C3 CCR6 CD19 CD4 CD40LG CD5
4 renal/urinary system MP:0005367 9.23 C3 CD19 CD40LG CD55 CD59 CD8A

Drugs & Therapeutics for Anemia, Autoimmune Hemolytic

Drugs for Anemia, Autoimmune Hemolytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4 Immunologic Factors Phase 4
5 Antirheumatic Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Immunosuppressive Agents Phase 4
8 Antibiotics, Antitubercular Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antimetabolites Phase 4
11 Antitubercular Agents Phase 4
12 Calcineurin Inhibitors Phase 4
13
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
14
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
16
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
19
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
21
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
22
Tretinoin Approved, Investigational, Nutraceutical Phase 2, Phase 3 302-79-4 444795 5538
23
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
24 Gastrointestinal Agents Phase 3
25 Methylprednisolone Acetate Phase 3
26 Antineoplastic Agents, Hormonal Phase 3
27 Antiemetics Phase 3
28 Neuroprotective Agents Phase 3
29 Hormone Antagonists Phase 3
30 glucocorticoids Phase 3
31 Protective Agents Phase 3
32 Anti-Inflammatory Agents Phase 3
33 Antibodies Phase 3
34 Immunoglobulins Phase 3
35 Autoantibodies Phase 3
36 Agglutinins Phase 3
37 Antifungal Agents Phase 2, Phase 3
38
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
39
Lenograstim Approved, Investigational Phase 2 135968-09-1
40
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
41
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
44
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
45
Lactitol Approved, Investigational Phase 1, Phase 2 585-88-6, 585-86-4 493591
46
Acyclovir Approved Phase 2 59277-89-3 2022
47
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
alemtuzumab Approved, Investigational Phase 2 216503-57-0
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients Completed NCT00494741 Phase 4 mycophenolate mofetil;azathioprine
2 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Recruiting NCT03918265 Phase 4 Tacrolimus
3 Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
4 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
5 Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3 Alemtuzumab, Rituximab
6 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
7 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT04138927 Phase 3 Fostamatinib disodium
8 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Active, not recruiting NCT03347422 Phase 3 Sutimlimab;Placebo
9 A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Active, not recruiting NCT03347396 Phase 3 Sutimlimab
10 Sirolimus Combined With All Trans Retinoic Acid for the Treatment of Auto-Immune Anemia Not yet recruiting NCT04324411 Phase 2, Phase 3 sirolimus and ATRA
11 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Suspended NCT04119050 Phase 2, Phase 3 M281;Placebo
12 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
13 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
14 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
15 CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 " Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Completed NCT02389231 Phase 1, Phase 2 Interleukine-2
17 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab Completed NCT01303952 Phase 2 Eculizumab
18 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine. Completed NCT00373594 Phase 2 Rituximab;Fludarabine
19 Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease Completed NCT01696474 Phase 2 Bortezomib
20 The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy Completed NCT02689986 Phase 2 Bendamustine, Rituximab
21 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
22 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
23 Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis. Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
24 A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP) Recruiting NCT04039477 Phase 2 KZR-616
25 A Phase II, Single-Center, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Recruiting NCT04398459 Phase 2 Ibrutinib
26 A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Recruiting NCT03538041 Phase 2 Parsaclisib
27 An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia Recruiting NCT04083014 Phase 2 combination of a single dose anti-CD20 antibody and bortezomib
28 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT02612558 Phase 2 Fostamatinib 150 mg bid
29 An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Active, not recruiting NCT03226678 Phase 2 APL-2
30 Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach Active, not recruiting NCT03827603 Phase 2 Ibrutinib
31 A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia Not yet recruiting NCT04253236 Phase 2 RVT-1401 680 mg/weekly;RVT-1401 340 mg/weekly
32 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Suspended NCT04256148 Phase 2
33 A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA) Terminated NCT03075878 Phase 1, Phase 2 ALXN1830
34 A Phase II Study of Alemtuzumab in Autoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
35 A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia Withdrawn NCT03965624 Phase 2 Ninlaro
36 High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia Completed NCT00001630 Phase 1
37 A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease Recruiting NCT04269551 Phase 1 BIVV020
38 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Recruiting NCT02502903 Phase 1 BIV009
39 Immunopathology of Autoimmune Hemolytic Anemia: an Open, Prospective and Multicenter Study Unknown status NCT02158195
40 One Year Hospital Data Patients With Autoimmune Hemolytic Anaemia in Assiut University Hospital - Clinical Hematology Unit Unknown status NCT03269292
41 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
42 Heavy Light Chain in Chronic Lymphocytic Leukemia Unknown status NCT02377869
43 National Study Backed by a Rare Disease Cohort the Benefit / Risk Balance of Immunomodulatory Treatments Prescribed in the Child and Adolescent for Autoimmune Cytopenia. Completed NCT04057703
44 National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia Completed NCT04070612
45 The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders Completed NCT00960713 Rituximab (MABTHERA® or RITUXAN®).
46 Prevalence of Autoantibodies in the Gaucher Disease and the Role of CD1 Molecules in Immune Manifestations of This Disease Completed NCT02650219
47 A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age Completed NCT01452464
48 Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo) Vaccination in Children 2 Through 10 Years of Age Completed NCT01452438
49 Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia Using Deuterated Water (GAC 0004) Completed NCT01110850
50 Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans Completed NCT00342641

Search NIH Clinical Center for Anemia, Autoimmune Hemolytic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Immunoglobulins, Intravenous

Cochrane evidence based reviews: anemia, hemolytic, autoimmune

Genetic Tests for Anemia, Autoimmune Hemolytic

Genetic tests related to Anemia, Autoimmune Hemolytic:

# Genetic test Affiliating Genes
1 Autoimmune Hemolytic Anemia 29

Anatomical Context for Anemia, Autoimmune Hemolytic

MalaCards organs/tissues related to Anemia, Autoimmune Hemolytic:

40
Testes, B Cells, T Cells, Liver, Bone, Bone Marrow, Thyroid

Publications for Anemia, Autoimmune Hemolytic

Articles related to Anemia, Autoimmune Hemolytic:

(show top 50) (show all 3099)
# Title Authors PMID Year
1
[Familial autoimmune hemolytic animia (AIHA) with negative Coombs test, lymphocytopenia and hypogammaglobulinemia]. 56 61
1209224 1975
2
Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis. 61 56
5660845 1968
3
Familial autoimmune haemolytic anaemia. 56
861649 1977
4
FAMILIAL AUTO-IMMUNE HEMOLYTIC ANEMIA. 56
14315660 1965
5
"ACQUIRED" ANTIBODY HEMOLYTIC ANEMIA AND FAMILIAL ABERRATIONS IN GAMMA GLOBULINS. 56
14124686 1964
6
Immuno-hemolytic anemia with familial occurence. 56
13007407 1952
7
Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. 54 61
20376581 2010
8
Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. 61 54
20374393 2010
9
Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. 54 61
18980619 2009
10
[Density-specific distribution of erythrocytes in different types of anemia]. 61 54
19253711 2009
11
Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. 61 54
18954403 2009
12
Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia. 54 61
18320220 2008
13
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 54 61
17289551 2007
14
Aortic valve replacement for a patient with glucose-6-phosphate dehydrogenase deficiency and autoimmune hemolytic anemia. 61 54
15985145 2005
15
Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. 61 54
14641141 2003
16
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. 61 54
12728121 2003
17
Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. 54 61
15373694 2003
18
Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. 61 54
12871191 2003
19
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]. 61 54
11930678 2001
20
[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test]. 61 54
10472686 1999
21
Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. 61 54
9787330 1998
22
Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti-red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A. 61 54
7517724 1994
23
Recurrent checkpoint inhibitor-induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma. 61
32243616 2020
24
Sirolimus for treatment of refractory primary warm autoimmune hemolytic anemia in children. 61
32220699 2020
25
Hemolytic Anemia as Presentation of T-Cell Large Granular Lymphocytic Leukemia After Kidney Transplantation: A Case Report. 61
32505499 2020
26
FcRn augments induction of tissue factor activity by IgG-containing immune complexes. 61
32187355 2020
27
Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis. 61
32524729 2020
28
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. 61
32557088 2020
29
Tolerization of recent thymic emigrants is required to prevent RBC-specific autoimmunity. 61
32507505 2020
30
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures. 61
32274943 2020
31
Risk of incident autoimmune diseases in patients with thymectomy. 61
32478484 2020
32
Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. 61
32577278 2020
33
Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia. 61
32485715 2020
34
COVID-19 infection associated with autoimmune hemolytic anemia. 61
32542444 2020
35
Bortezomib for autoimmune hemolytic anemia after intestinal transplantation. 61
32166874 2020
36
COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. 61
32495391 2020
37
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL. 61
32548659 2020
38
Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia. 61
32548660 2020
39
[Detection of Autoimmune Hemolytic Anemia Induced by Salvianolate and Evaluation of Blood Transfusion Efficacy]. 61
32552956 2020
40
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review. 61
32234571 2020
41
BK virus encephalitis and end-stage renal disease in a child with hematopoietic stem cell transplantation. 61
32412694 2020
42
Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia. 61
31997080 2020
43
Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. 61
32362156 2020
44
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. 61
32548562 2020
45
A novel frame shift mutation in STIM1 gene causing primary immunodeficiency. 61
32494559 2020
46
Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: A systematic review and meta-analysis of randomized controlled trials. 61
32384203 2020
47
[RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA - GOOD RESPONSE TO RITUXIMAB TREATMENT]. 61
32431123 2020
48
Daratumumab for refractory warm autoimmune hemolytic anemia. 61
32405694 2020
49
Systemic lupus erythematosus complicated by a Gitelman-like syndrome in an 8-year-old girl. 61
31853802 2020
50
[Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study]. 61
32536139 2020

Variations for Anemia, Autoimmune Hemolytic

Expression for Anemia, Autoimmune Hemolytic

Search GEO for disease gene expression data for Anemia, Autoimmune Hemolytic.

Pathways for Anemia, Autoimmune Hemolytic

Pathways related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 ICOSLG HP CTLA4 CD8A CD59 CD55
2
Show member pathways
12.5 ICOSLG FOXP3 CTLA4 CD8A CD55 CD40LG
3 12.32 FOXP3 CTLA4 CD8A CD40LG CD19
4
Show member pathways
12.23 ICOSLG CTLA4 CD40LG CD4
5
Show member pathways
11.99 CD59 CD55 C3 C1S
6
Show member pathways
11.92 CD59 CD55 C3 C1S
7 11.9 CD59 CD55 C3 C1S
8 11.89 ICOSLG CTLA4 CD8A CD40LG CD4
9 11.8 CD8A CD40LG CD19 C3
10
Show member pathways
11.65 CD55 C3 C1S
11 11.64 CD8A CD4 CCR6
12
Show member pathways
11.59 FOXP3 CTLA4 CD40LG
13 11.57 CD8A CD4 CD19
14 11.54 CTLA4 CD8A CD4
15 11.5 GYPA CD8A CD59 CD5 CD4 CD19
16 11.16 GYPA CD8A CD59 CD55 CD5 CD4
17 11.14 CD8A CD40LG CD4 CD19

GO Terms for Anemia, Autoimmune Hemolytic

Cellular components related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.22 STIM2 RHCE LRBA ICOSLG GYPA G6PD
2 integral component of membrane GO:0016021 10.18 STIM2 RHCE LRBA ICOSLG GYPA CTLA4
3 plasma membrane GO:0005886 9.83 STIM2 LRBA ICOSLG GYPA CTLA4 CD8A
4 integral component of plasma membrane GO:0005887 9.81 RHCE GYPA CTLA4 CD8A CD5 CD40LG
5 cell surface GO:0009986 9.73 CD59 CD55 CD40LG CD4 CCR6 C3
6 external side of plasma membrane GO:0009897 9.23 ICOSLG CTLA4 CD8A CD5 CD40LG CD4

Biological processes related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.85 ICOSLG CTLA4 CD8A CD4 CD19
2 immune response GO:0006955 9.85 CTLA4 CD8A CD40LG CD4 CCR6 C3
3 regulation of immune response GO:0050776 9.72 ICOSLG CD8A CD40LG CD19 C3
4 T cell receptor signaling pathway GO:0050852 9.71 ICOSLG FOXP3 CTLA4 CD4
5 T cell costimulation GO:0031295 9.56 ICOSLG CTLA4 CD5 CD40LG
6 negative regulation of immune response GO:0050777 9.51 FOXP3 CTLA4
7 respiratory burst GO:0045730 9.49 CD55 CD52
8 T cell mediated immunity GO:0002456 9.48 FOXP3 CD8A
9 T cell activation GO:0042110 9.46 ICOSLG FOXP3 CD8A CD4
10 regulation of complement-dependent cytotoxicity GO:1903659 9.43 CD59 CD55
11 regulation of complement activation GO:0030449 9.35 CD59 CD55 CD19 C3 C1S
12 immune system process GO:0002376 9.28 ICOSLG HP CTLA4 CD8A CD55 CD4

Molecular functions related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 STIM2 LRBA ICOSLG HP GYPA G6PD
2 virus receptor activity GO:0001618 9.13 GYPA CD55 CD4

Sources for Anemia, Autoimmune Hemolytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....